The Application of Cyclin-Dependent Kinase Inhibitors to Treat Breast Cancer Among Older Patients

The Application of Cyclin-Dependent Kinase Inhibitors in Treating Breast Cancer

The medical advances journal used in this paper is about the application of cyclin-dependent kinase inhibitors to treat breast cancer among older patients with an ER-positive HER2-negative type of breast tumor (Battisti et al. 1). The date of the publication of the journal is November 20, 2018. The identity of the inhibitor is CDK4\/6, and the review journal belongs to the Young International Society of Geriatric Oncology. Authors of the medical journal include Nienke De Glas, Gabor Liposits, Nicolò Matteo Luca Battisti, Mina S. Sedrak, Alistair Ring, Enrique Soto-Perez-de-Celis, Ines B. Menjak, Kah Poh Loh, and Jessica L. Krok-Schoen. The audiences of the journal include medical practitioners and the general public. The revision of the review happened on September 20, 2018, and the media source of the journal is Sage Journals, and the link is: https://journals.sagepub.com/doi/full/10.1177/1758835918809610

Age as a Risk Factor for Breast Cancer

According to the journal, age is one of the known risk factors relating to breast cancer, and there is an expectation of the element to increase such risk shortly. The researchers also claim that breast cancer is a common cancer diagnosis in women (Battisti et al. 1). The idea of introducing the new cyclin-dependent kinase inhibitors with the identity of CDK4\/6 would be a breakthrough in the current treatment of breast cancer as the journal explains. The researchers continue to demonstrate how adult women aged 60 years and above fall under the majority of breast cancer patients in the entire world. However, there is a challenge in determining the specific dosing, the benefit of the inhibitors, and their tolerability. As a result, clinical trials cannot involve older patients, and clinicians have to do their research on younger individuals to make decisions on how older patients can get their dosage. The journal proposes potential approaches that can help in making informed decisions based on the reactions of older cancer patients to CDK 4\/6 inhibitors (Battisti et al. 4). Lastly, the journal claims that some clinical trials are in session right now to evaluate the use of CDK 4\/6 inhibitors to treat breast cancer.

Work Cited

Battisti, N De Glas et al. et al. “Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper.” Sage Journals (2018).